dpp-4 inhibitor and glp-1 receptor agonist combination Dipeptidyl peptidase-4 The pharmacology of DPP-4 inhibitors
Description
Nuwayhid said
Exenatide once a week assisted more patients in reaching the majority of ADA-recommended therapeutic goals than treatment with sitagliptin, pioglitazone, or insulin glargine
Draw the prescribed volume carefully
Among the 316 patients (60.9 years [52.168.9] of age
placebo: n = 2 (2.4%)] ( Psychiatric AEs are a less frequent class of adverse reactions associated with GLP-1 RAs
10.1210/jcem-24-10-1076 37 EverardA.LazarevicV.DerrienM.GirardM.MuccioliG
